Ryan Quick

Mr. Quick has over 22 years of experience in the life sciences industry, spanning both large pharma and biotech startups with experience ranging from current Good Manufacturing Practice production to bench research. Prior to joining Lisata, Mr. Quick started a successful Chemistry, Manufacturing, and Controls (CMC) consulting business, helping clients all over the world develop peptide/oligonucleotide/ADC therapies and diagnostics. Additionally, Mr. Quick was a co-founder of Drive Therapeutics, a company targeting the wet Age Related Macular Degeneration and Diabetic Macular Edema populations with next-generation aptamer therapies. Prior to co-founding Drive, Mr. Quick was the Head of Research Chemistry at Vitrisa Therapeutics where he was responsible for compound synthesis to support discovery, biology, and drug metabolism and pharmacokinetics. In addition, Mr. Quick’s group was responsible for analysis of internal compounds and oligo conjugation, and he worked closely with the CMC group to provide research support. Prior to joining Vitrisa, Mr. Quick led the analytical development and validation group at Novan Therapeutics and was an integral part of the team that moved the main candidate from Phase 2 to Phase 3 at Regado Biosciences. Mr. Quick received his B.Sc. in Chemical Engineering from NC State University.